目的 探討舒眠膠囊聯(lián)合右佐匹克隆片治療失眠癥的臨床療效。方法 選擇2016年1月-2017年2月陜西省人民醫(yī)院收治的失眠癥患者112例作為研究對(duì)象，將所有患者隨機(jī)分為對(duì)照組和治療組，每組各56例。對(duì)照組口服右佐匹克隆片，3 mg/次，1次/d。治療組在對(duì)照組基礎(chǔ)上于晚飯后臨睡前口服舒眠膠囊，1.2 g/次，2次/d。兩組患者均治療4周。觀察兩組的臨床療效，比較兩組的匹茲堡睡眠質(zhì)量指數(shù)（PSQI）評(píng)分、促甲狀腺激素（TSH）、三碘甲狀腺氨酸（T3）和甲狀腺素（T4）水平。結(jié)果 治療后，對(duì)照組和治療組的總有效率分別為82.14%、94.64%，兩組比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，兩組睡眠時(shí)間、主觀質(zhì)量、入睡時(shí)間、睡眠障礙、睡眠效率、日間功能、藥物應(yīng)用和PSQI評(píng)分均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。治療后，治療組TSH、T3和T4水平均明顯降低，同組治療前后比較差異有統(tǒng)計(jì)學(xué)意義（P<0.05）；且治療組這些觀察指標(biāo)明顯低于對(duì)照組，兩組比較差異具有統(tǒng)計(jì)學(xué)意義（P<0.05）。結(jié)論 舒眠膠囊聯(lián)合右佐匹克隆片治療失眠癥具有較好的臨床療效，能改善臨床癥狀，調(diào)節(jié)甲狀腺激素水平，安全性較好，具有一定的臨床推廣應(yīng)用價(jià)值。

Objective To investigate the clinical efficacy of Shumian Capsules combined with Eszopiclone Tablets in treatment of insomnia. Methods Patients (112 cases) with insomnia in Shaanxi Provincial People's Hospital from January 2016 to February 2017 were randomly divided into control and treatment groups, and each group had 56 cases. Patients in the control group were po administered with Eszopiclone Tablets, 3 mg/time, once daily. Patients in the treatment group were po administered with Shumian Capsules after dinner and before sleep on the basis of the control group, 1.2 g/time, once daily. Patients in two groups were treated for 4 weeks. After treatment, the clinical efficacies were evaluated, and PSQI scores and the levels of TSH, T3, and T4 in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 82.14% and 94.64%, respectively, and there was difference between two groups (P<0.05). After treatment, the scores of sleep time, subjective quality, fall asleep time, sleep disorders, sleep efficiency, daytime function, drug use, and PSQI in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of TSH, T3 and T4 in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). Conclusion Shumian Capsules combined with Eszopiclone Tablets has clinical curative effect in treatment of insomnia, can improve clinical symptoms and regulate thyroid hormone level, with less adverse reaction, which has a certain clinical application value.